Cynata Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Cynata Therapeutics's earnings have been declining at an average annual rate of -16.2%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been declining at an average rate of 7.6% per year.
Anahtar bilgiler
-16.2%
Kazanç büyüme oranı
-3.5%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 9.6% |
Gelir büyüme oranı | -7.6% |
Özkaynak getirisi | -135.0% |
Net Marj | -420.8% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Güncelleme yok
Recent updates
Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Sep 21Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?
May 29We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate
Feb 09We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow
Feb 02We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth
Sep 09Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
May 26Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Dec 31We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn
Aug 11Gelir ve Gider Dağılımı
Cynata Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 2 | -10 | 2 | 9 |
31 Mar 24 | 2 | -12 | 2 | 11 |
31 Dec 23 | 2 | -14 | 2 | 12 |
30 Sep 23 | 2 | -14 | 2 | 12 |
30 Jun 23 | 2 | -14 | 2 | 12 |
31 Mar 23 | 2 | -12 | 2 | 11 |
31 Dec 22 | 3 | -9 | 2 | 9 |
30 Sep 22 | 5 | -7 | 2 | 9 |
30 Jun 22 | 8 | -5 | 3 | 9 |
31 Mar 22 | 8 | -5 | 5 | 6 |
31 Dec 21 | 8 | -4 | 7 | 4 |
30 Sep 21 | 5 | -6 | 5 | 4 |
30 Jun 21 | 2 | -8 | 3 | 4 |
31 Mar 21 | 2 | -7 | 2 | 5 |
31 Dec 20 | 3 | -6 | 0 | 6 |
30 Sep 20 | 5 | -5 | 1 | 6 |
30 Jun 20 | 7 | -4 | 2 | 6 |
31 Mar 20 | 6 | -6 | 3 | 6 |
31 Dec 19 | 4 | -8 | 4 | 6 |
30 Sep 19 | 3 | -8 | 3 | 6 |
30 Jun 19 | 1 | -8 | 2 | 6 |
31 Mar 19 | 1 | -7 | 2 | 4 |
31 Dec 18 | 1 | -6 | 2 | 3 |
30 Sep 18 | 1 | -5 | 2 | 3 |
30 Jun 18 | 1 | -5 | 1 | 3 |
31 Mar 18 | 1 | -5 | 1 | 3 |
31 Dec 17 | 1 | -5 | 1 | 3 |
30 Sep 17 | 2 | -5 | 1 | 3 |
30 Jun 17 | 2 | -5 | 1 | 3 |
31 Mar 17 | 2 | -4 | 1 | 4 |
31 Dec 16 | 2 | -3 | 0 | 4 |
30 Sep 16 | 1 | -4 | 1 | 4 |
30 Jun 16 | 1 | -5 | 1 | 4 |
31 Mar 16 | 1 | -5 | 2 | 3 |
31 Dec 15 | 1 | -5 | 3 | 2 |
30 Sep 15 | 1 | -4 | 2 | 2 |
30 Jun 15 | 0 | -4 | 1 | 2 |
31 Mar 15 | 0 | -3 | 2 | 1 |
31 Dec 14 | 0 | -3 | 2 | 1 |
30 Sep 14 | 0 | -3 | 2 | 1 |
30 Jun 14 | 0 | -3 | 2 | 1 |
31 Mar 14 | 0 | -3 | 2 | 0 |
31 Dec 13 | 0 | -2 | 1 | 0 |
Kaliteli Kazançlar: CYP is currently unprofitable.
Büyüyen Kar Marjı: CYP is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: CYP is unprofitable, and losses have increased over the past 5 years at a rate of 16.2% per year.
Büyüme Hızlandırma: Unable to compare CYP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: CYP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.5%).
Özkaynak Getirisi
Yüksek ROE: CYP has a negative Return on Equity (-135.02%), as it is currently unprofitable.